Bolt Biotherapeutics, Inc.
Clinical trials sponsored by Bolt Biotherapeutics, Inc., explained in plain language.
Develops immuno-oncology therapies using antibody-drug conjugates and immune-stimulating payloads.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New breast cancer drug trial halted early – what we know
Disease control TerminatedThis study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with multiple therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink t…
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study tested a new drug called BDC-3042, alone or with another drug (cemiplimab), in 17 people with advanced cancers like breast, kidney, ovarian, head and neck, colorectal, lung, or melanoma. The main goal was to check safety and find the right dose. The study w…
Phase: PHASE1 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Experimental cancer combo trial halted early – what it means for patients
Disease control TerminatedThis early-stage trial tested a new drug called BDC-1001, alone or with the immunotherapy nivolumab, in 175 people with advanced HER2-positive cancers (like breast, colorectal, and stomach cancers) that had stopped responding to other treatments. The study aimed to check safety a…
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:13 UTC